The Administration for Strategic Preparedness and Response July 16 announced it will work with the Department of Commerce on an assessment of the active pharmaceutical industrial base to better understand the pharmaceutical supply chain and how it has changed since the COVID-19 pandemic. The assessment is based on a survey conducted last winter. The study will inform federal strategies and funding decisions related to the API supply chain and raise awareness of potential supply chain issues, such as the current limited domestic manufacturing capabilities and other potential issues. The study will survey more than 200 companies, including manufacturers, distributors, suppliers and customers. A Bureau of Industry and Security webpage answers FAQs about the project.
 

Headline
The Food and Drug Administration June 16 announced that a nationwide shortage of stereotactic breast biopsy needles is expected to last through the end of…
Headline
The Administration for Strategic Preparedness and Response June 16 announced the launch of the Digital Stockpile and Manufacturing Response Network Challenge,…
Headline
The U.S. Trade Representative yesterday announced plans to impose additional tariffs on goods from certain nations that it said had lacked or failed…
Headline
The Food and Drug Administration announced May 6 that it is aware of a shortage of neurosurgical patties, sponges and strip devices across the U.S. due to…
Headline
The Health Sector Coordinating Council’s Cybersecurity Working Group has released a guide on third-party artificial intelligence risk and AI supply…
Headline
The White House April 2 issued a proclamation implementing additional tariffs on certain patented pharmaceutical products and ingredients. The order imposes a…